175 related articles for article (PubMed ID: 38486447)
1. CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis.
Masucci L; Tian F; Tully S; Feng Z; McFarlane T; Chan KKW; Wong WWL
Med Decis Making; 2024 Apr; 44(3):296-306. PubMed ID: 38486447
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
[TBL] [Abstract][Full Text] [Related]
3. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective.
Cher BP; Gan KY; Aziz MIA; Lin L; Hwang WYK; Poon LM; Ng K
J Med Econ; 2020 Nov; 23(11):1321-1329. PubMed ID: 32780608
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.
Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A
Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view.
Thielen FW; van Dongen-Leunis A; Arons AMM; Ladestein JR; Hoogerbrugge PM; Uyl-de Groot CA
Eur J Haematol; 2020 Aug; 105(2):203-215. PubMed ID: 32289184
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
Furzer J; Gupta S; Nathan PC; Schechter T; Pole JD; Krueger J; Pechlivanoglou P
JAMA Oncol; 2020 Mar; 6(3):393-401. PubMed ID: 31971547
[TBL] [Abstract][Full Text] [Related]
10. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Pediatr; 2018 Dec; 172(12):1161-1168. PubMed ID: 30304407
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
Oluwole OO; Ray MD; Davies N; Bradford R; Jones C; Patel AR; Locke FL
J Med Econ; 2024; 27(1):230-239. PubMed ID: 38240256
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
[TBL] [Abstract][Full Text] [Related]
14. Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
Wu W; Zhou Y; Wang Y; Keramat SA; Balasooriya NN; Zhao Z; Yang Y; Comans T; Dong H
Appl Health Econ Health Policy; 2023 Sep; 21(5):773-783. PubMed ID: 37356080
[TBL] [Abstract][Full Text] [Related]
15. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective.
Yang H; Hao Y; Chai X; Qi CZ; Wu EQ
J Med Econ; 2020 Sep; 23(9):1016-1024. PubMed ID: 32397772
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan.
Wakase S; Teshima T; Zhang J; Ma Q; Watanabe Y; Yang H; Qi CZ; Chai X; Xie Y; Wu EQ; Igarashi A
Transplant Cell Ther; 2021 Mar; 27(3):241.e1-241.e11. PubMed ID: 33781519
[TBL] [Abstract][Full Text] [Related]
19. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.
Lin JK; Lerman BJ; Barnes JI; Boursiquot BC; Tan YJ; Robinson AQL; Davis KL; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2018 Nov; 36(32):3192-3202. PubMed ID: 30212291
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective.
Wang XJ; Wang YH; Li SCT; Gkitzia C; Lim ST; Koh LP; Lim FLWI; Hwang WYK
J Med Econ; 2021; 24(1):637-653. PubMed ID: 33904359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
